In February 2024, the U.S. Food and Drug Administration (FDA) approved Xolair (Omalizumab) for patients 1 year of age and older at risk for immunoglobulin E (IgE)-mediated food allergic reactions after accidental exposure. Xolair has been on the market for 20 years, and at Schreiber Allergy, we ... Read more »
Food Allergy
Food Allergy vs. Food Intolerance
Here at Schreiber Allergy, we are getting many questions and visits related to food intolerance. We hope that this post can answer some common questions regarding the differences between food allergy and food intolerance. It is true that adverse reactions to foods are very common. But it is ... Read more »